Questions we actually get

The standard price is €2,500. A launch price of €1,500 applies to the first 5 paid diagnostic engagements, until 31 December 2026. Because launch places are limited, eligibility for the launch price is confirmed in writing before payment. The scope is fixed: one legal entity, one profitability lens and up to 12 months of data. Larger or multi-entity work and any implementation are scoped separately. Taxes, where applicable, are confirmed before payment.

7–10 business days, fixed scope, from the point we have the data we need.

An evidence-supported opportunity map, an economic exposure model with source and calculation lineage, an expected recoverable-value range with assumptions and confidence where recoverability can be defensibly estimated, a cause / mechanism assessment, prioritized intervention cases, and a measurement plan for after implementation. Not every Diagnostic produces six positive findings: “evidence insufficient”, “hypothesis rejected” or “intervention not justified” are valid outcomes, and are reported as such.

It depends on the company and the problem identified — not every Diagnostic requires every dataset. Typical inputs include P&L or management accounts, revenue by client/project/product/location where available, payroll and capacity data, CRM/ERP exports, AR/AP or working-capital data, and 1–3 workflow walkthroughs with your team.

Typically 3–5 hours across the engagement, mostly for data access and short workflow walkthroughs.

No. The Diagnostic is a standalone engagement. If the economics justify intervention, you can implement internally, use another provider, or continue with Aigenrix. You keep the analysis either way.

They often could, in principle — but they own individual functions and the daily operation, which makes an independent, cross-functional view harder to build from inside. Aigenrix combines finance, operations, process architecture and data into one model, giving management an integrated economic and operating picture it did not have before.

Before implementation we model it: the baseline cost of the problem, the intervention cost, an estimated effect with a sensitivity range, and the resulting payback. That is a projection, not a result. Realized ROI is measured only after implementation, against the agreed baseline.

We do not ask you to simply trust our recommendation, and we do not guarantee outcomes that depend on implementation and business conditions. We establish a baseline and evidence the economic problem first. Then, where it can be defensibly estimated, we estimate the expected recoverable value, implementation cost, expected benefit range, payback and key risks. Where uncertainty is material, we do not recommend moving directly to full-scale implementation. We first test the intervention through a limited pilot with predefined success criteria. After implementation, actual results are measured against the baseline. If the economics are not validated, the intervention is not scaled. The objective is not to guarantee that every idea will work. It is to reduce the risk of committing significant capital to an intervention before its economics have been evidenced and tested.

No. Aigenrix tests economically relevant hypotheses within an agreed scope and evidence set. It reports what the evidence supports and does not claim completeness beyond that scope.

Then that is the finding: no additional material opportunity identified within the tested scope. It does not mean none exist outside that scope or evidence set — and you keep the analysis.

No. Public information helps prioritize what to investigate. Client-specific monetary findings require appropriate internal or otherwise defensible evidence.

Not by itself. A benchmark may trigger an investigation, but the comparator must be relevant and the economic mechanism must be supported. Your own history, internal comparisons, contractual or engineering standards and explicit counterfactuals are often stronger references.

No. Before implementation Aigenrix can model expected economics and scenarios. Realized value is measured only after implementation.

No. Much of the analysis can be automated. Human review is retained for decisions where business meaning, causality or feasibility cannot be established defensibly from data alone.

We say so. Some findings only require pricing, management, process or policy changes — no AI at all. We do not need to sell technology to make the Diagnostic worth running.

Normally, yes — we work with the stack you already have where that is economically and technically sensible, rather than defaulting to a rip-and-replace. We cannot promise compatibility with every system, but replacing tools is the exception, not the starting assumption.

Aigenrix searches for likely profit, cash and operational losses, asks for the minimum evidence needed to test them, quantifies only what the evidence supports, and helps management decide what is economically worth fixing. AI, automation and security are applied only where the economics justify them — not as the starting point.

A structured model of how people, processes, systems, data, costs, decisions and dependencies actually interact — built from your real data, not a generic template. It lets us simulate a change before committing to it, and is used only where a finding involves multiple processes, roles, systems or dependencies.

As a control layer across the redesigned operation — covering data, identity, permissions, AI-agent access, integrations and monitoring for the sensitive business information the new system touches. Security is built into the redesign, not bolted on afterward.

Businesses with roughly €1M–€30M in annual revenue and 10–250 employees, with sufficient financial and operational data, where management sees margin pressure or profitability differences but cannot yet explain their economic causes. It is a fit indicator, not a hard condition.

A free 30-minute review. On the call we understand the economic symptoms, identify which data would likely be required, assess whether the leakage appears material enough to investigate, and decide whether a paid step is justified: an Expert Decision Session or the Margin Leakage Diagnostic. If we do not see a credible case, we will tell you.